This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Information update

New safety information for antiviral drug used in the treatment of HIV

Starting date:
February 19, 2014
Posting date:
February 19, 2014
Type of communication:
Information Update
Source of recall:
Health Canada
New safety information
General Public
Identification number:


Health Canada is informing health professionals and patients of new safety information regarding TELZIR (fosamprenavir calcium), an antiviral drug, used in combination with other antiviral agents to treat Human Immunodeficiency Virus (HIV) infection in adults and children 6 years of age and older.

TELZIR should not be used with the antiarrhythmic drugs amiodarone, lidocaine (systemic), or quinidine, as this may cause serious and/or life-threatening reactions such as abnormal heart rhythm (arrhythmias).

In addition, Telzir should not be used with delavirdine, another antiviral drug to treat HIV, because it may reduce the effectiveness of delavirdine.

The product labels have been updated to better reflect the new recommendations regarding the safe use of these medicines.

What you should do

  • Talk to a healthcare professional regarding any questions or concerns you may have about your treatment.
  • Do not stop treatment without consulting with your doctor or healthcare professional.

Report health or safety concerns

To report a side effect to a health product to Health Canada:

  • Call toll-free at 1-866-234-2345
  • Visit Health Canada’s Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

Media enquiries

Health Canada

(613) 957-2983

Public enquiries

(613) 957-2991

1-866 225-0709